Navigation Links
NeoStem, Inc. to Present at NASDAQ MarketSite
Date:5/12/2010

NEW YORK, May 12 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that its CEO will present at the NASDAQ MarketSite in Times Square, New York City.

NeoStem's CEO, Dr. Robin Smith will provide corporate updates and discuss important advances in the Company's business.

When: May 25, 2010, 1:00 pm EDT

Where: NASDAQ MarketSite, 4 Times Square, New York, NY

RSVP required for building security: 917-680-6011, bradley.smith@muncmedia.com

To watch the event on 5/25, 1:00 pm EDT, please click http://mktvideo.nasdaq.com/marketsitetowervideo2 .

Dr. Smith will be available for media and analyst interviews. Please call 917-680-6011 to schedule.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSELTM technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit our new website: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to advances in the Company's stem cell technologies, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

    For more information, please contact:

    NeoStem, Inc.
     Robin Smith, CEO
     Phone: +1-212-584-4174
     Email: rsmith@neostem.com
     Web:   http://www.neostem.com


'/>"/>
SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
2. NeoStem, Inc. Awarded NIH Research and Research Infrastructure Grand Opportunities Grant
3. NeoStem, Inc. is Certified by the State of New York as a Qualified Emerging Technology Company and Notifies Investors of Possible Tax Credit of up to 20%
4. NeoStem, Inc. Appoints Leading Chinese Medical Official to Its Advisory Board
5. NeoStem, Inc. Appoints Financial Expert with Broad International Experience to the Board of Directors and to Serve as Chairman of the Companys Audit Committee
6. NeoStem, Inc. Announces Agreement With Progenitor Cell Therapy, LLC
7. NeoStem, Inc. to Enter the Regenerative Medicine Market in Asia
8. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
9. Suzanne Somers To Promote Growing Importance of Storing Your Own Adult Stem Cells Under Alliance With NeoStem, Inc.
10. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
11. Onyx Pharmaceuticals to Present at the Baird 2010 Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... three states, announced today the promotion of two long-standing principal investigators (PI) to ... Family Medicine, Clinical Research and Development. , Dr. Laurence Chu, a Benchmark Research ...
(Date:2/10/2016)... ... February 10, 2016 , ... PatientCrossroads ... on the secure online PatientCrossroads platform, has exceeded both its one-year and overall ... the PROMPT study, which seeks to advance understanding of the hereditary risks for ...
(Date:2/10/2016)... ... February 09, 2016 , ... Creation Technologies, leading ... the Highest Overall Customer Rating Award from Circuits Assembly , today announced its ... the USA, Canada, Mexico and China. , The EMS provider, known in the ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
Breaking Biology News(10 mins):